The enhanced green fluorescent protein (eGFP) is minimally immunogenic in C57BL/6 mice
The development of immunologic responses to the products of transferred genes is a potentially limiting factor in the correction of genetic diseases by gene therapy. The nature of these responses depends on numerous factors which affect the immunogenicity of the transgene product, including differences between the transgene product and endogenous proteins, the type of cell which produces the gene product, and the MHC repertoire of the host. Proteins expressed as selectable markers may also be immunogenic, as described by Riddell et al. 1 We previously reported that the enhanced green fluorescent protein (eGFP), which is used as a reporter gene detectable by fluorescent microscopy or flow cytometry, is immunogenic when expressed in a Balb/c-derived leukemia cell line transformed by the p185 bcr/abl fusion oncogene (BM185), administered intravenously. 2 Cytotoxic T lymphocytes (CTL) were readily detectable which reacted against BM185 cells expressing eGFP (BM185/eGFP), but not against the parental BM185 cells.
During the review process for the above-referenced manuscript, we were asked by a reviewer to determine whether the immunologic responses seen against eGFP when expressed by the BM185 cell line in Balb/c mice are generalized to other cell lines and strains of mice. Therefore, a similar experiment was done using the EL-4 murine T cell lymphoma line in the syngeneic C57BL/6 host. Unmodified EL-4 cells grew into large tumors within 25 days when implanted subcutaneously, but no tumors formed from a clone of EL-4 cells expressing eGFP (EL-4/eGFP) at 30 days ( Figure 4 , in Stripecke et al 2 ) . This study suggested that eGFP was also immunogenic in C57BL/6 mice.
Following publication of that report, studies were begun to characterize the nature of the immune response to the eGFP protein expressed by the EL-4 lymphoma cells. C57BL/6 mice were given irradiated (20 Gy) EL-4/eGFP cells i.v. or s.c., but CTL reacting against EL-4 cells expressing eGFP were not detected. To determine whether the lack of CTL responses to eGFP when expressed by C57BL/6 cells, but not when expressed by BM185 cells, was due to the different routes of administration or due to differences in the immune responses of the two strains of mice, we simultaneously compared the immune responses in these two models. Cohorts of Balb/c and C57BL6 mice were administered BM185/eGFP or EL-4/eGFP cells respectively, comparing intravenous to subcutaneous routes of administration (Table 1 ). In the Balb/c mice given BM185 cells intravenously, none of five mice died after being given BM185/eGFP cells, compared with four of five mice which died after developing systemic leukemia with wild-type BM185 cells. These data are consistent with prior observations on the immunogenicity of eGFP when expressed from BM185 cells in Balb/c mice. 2 When we gave the BM185 cells subcutaneously, however, the mice all developed rapidly growing subcutaneous tumors within 20 days, whether the cells were transduced with eGFP or not. This result suggested that the route of cell administration was important, either to initiate an antieGFP immune response, or for it to be effective in the elimination of the eGFP-expressing leukemia cells.
The EL-4 cells given intravenously did not cause any deaths in C57BL/6 mice, whether transduced with eGFP or not. Given subcutaneously, the non-modified EL-4 cells produced tumors in 100% of the mice within 20-25 days. As we observed previously, 2 the EL-4/eGFP cells did not cause detectable tumors before 30 days. However, when followed for a longer time, tumors did develop from the EL-4/eGFP cells in four of five mice over the second month. The delayed growth of EL-4/eGFP cells in C57BL/6 mice may indicate a weak immune response against eGFP which delayed tumor development, but was not sufficiently strong to reject the cells completely or be detected in a CTL assay.
Subsequently, GFP-transduced C57BL/6 bone marrow or eGFP-transduced dendritic cells derived from C57BL/6 bone marrow were injected intravenously into syngeneic mice given no radiation or relatively low dosages of total-body irradiation (eg 1-2 Gy). We did not detect any in vivo immune responses (elimination of eGFP-transduced marrow cells) or in vitro CTL responses in the recipients. These findings, coupled with those of Denaro et al 7 (vide infra), suggest that eGFP is not highly immunogenic in C57BL/6 mice.
Clearly, eGFP is immunogenic in Balb/c mice and, as reported recently, in rhesus macaque monkeys. 3 The lack of immunogenicity of this protein in C57BL/6 mice may be an exception rather than the rule. C57BL/6 mice have also been noted to have relatively weak immunologic responses to adenoviral vector proteins and human factor IX protein, compared with a number of other mouse strains. [4] [5] [6] Our original caution pertaining to the use of eGFP as a selectable marker for in vivo studies, especially those intended for human subjects remains valid. We now propose the additional caution that eGFP may be a poor indicator of immune responses or induction of tolerance to transgene products in C57BL/6 mice. 
EGFP-transduced EL-4 cells form tumors in C57BL/6 mice
The immunogenicity of the enhanced green fluorescent protein (EGFP) has recently been demonstrated in mice. 1, 2 In particular, syngeneic tumor cells transduced with retroviral (RV) vectors expressing EGFP have been reported to be rejected following transplantation in immunocompetent C57BL/6 and BALB/c recipients. 1 In the BALB/c mouse strain, the mechanism for rejection of CMS4 sarcoma and BM185 leukemia cells has been shown to be mediated by cytotoxic T-lymphocytes (CTLs) that recognize the foreign EGFP peptides.
1,2 Furthermore, CTL responses have been observed in rhesus monkeys receiving a low nonmyeloablative dose of radiation and EGFP-transduced autologous hematopoietic cells. 3 Attracted by the technical ease of using rejection in a solid tumor model for studying immunological tolerance, our laboratory has conducted a set of experiments using EL-4 T cell lymphoma cells growing in C57BL/6 mice, similar to those described by Stripecke et al. 1 Briefly, EL-4 cells (ATCC, Rockville, MD, USA) were transduced with a RV vector denoted GBiP. This vector contains an EGFP (G) cDNA followed by the human immunoglobulin heavy chain binding protein (BiP) which is an internal ribosomal entry site (IRES) inserted in a pLN 4 backbone modified with a myeloproliferative sarcoma virus (MPSV) enhancer in the 3'LTR. 5 The plasmid pGBiP-6 was deposited with the ATCC (No. PTA 2498).
An EGFP + EL-4 clone (EL4xEGFP) was established that has stable EGFP expression with a mean fluorescence intensity of approximately 1000-fold above nontransduced wild-type (wt) cells. Additionally, EL-4 cells expressing the marker neo were established (EL4-neoR) by transduction with an amphotropic pLXSN 4 vector and selection in 1 mg/ml G418. A neo-resistant pool of the EGFP+ EL-4 clone was established also by transduction with pLXSN (EL4xEGFP-neoR).
In four separate experiments using a dose of 5 × 10 antibody (Clone KH95; PharMingen, San Diego, CA, USA) and found to be equivalent to wt EL-4 cells. We reasoned that the detection of immunological rejection might depend on the size of the tumor cell inoculum. However, this did not appear to be a significant factor as a lack of growth inhibition of EGFP-transduced EL-4 cells, as compared with the wt cells was also seen at lower cell doses (Figure 1) . In a separate experiment, neoR-transduced EL-4 cells, with or without co-transduction with EGFP, all formed tumors. Therefore, our results appear to be at variance with the previous findings of Stripecke et al 1 who reported that three mice inoculated with EL-4 cells containing both neomycin resistance and EGFP genes failed to develop tumors. We would con-
